Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
MRONJ after tooth extraction (incidence proportion) · People on antiresorptive treatment undergoing tooth extraction (at risk of MRONJ)
Subperiosteal prepared (SPP) wound closure after tooth extraction showed no clear difference in MRONJ after tooth extraction (incidence proportion) compared with epiperiosteal prepared (EPP) wound closure after tooth extraction (low certainty).
1 finding from 1 review
Intervention not reported
Antibiotics prior to long‐term CVC insertion versus control: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
The intervention showed no clear difference in antibiotics prior to long‐term CVC insertion versus control:… (moderate certainty).
1 finding from 1 review
Intervention not reported
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
The intervention probably leads to lower antibiotic versus heparin only lock/flush solution: catheter‐related… (moderate certainty).
1 finding from 1 review
Intervention not reported
Antibiotic versus heparin only lock/flush solution: adverse events · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
1 finding from 1 review
Long‐term recurrence (> 5 years) · people with GSV incompetence
It is very uncertain whether endovenous laser ablation (EVLA) changes long‐term recurrence (> 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).
1 finding from 1 review
Complications (up to 8 years) · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
QoL · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Technical success · people with GSV incompetence
Endovenous laser ablation (EVLA) showed no clear difference in technical success (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (low certainty).
2 findings from 1 review
Recurrence · people with GSV incompetence
It is very uncertain whether endovenous laser ablation (EVLA) changes recurrence (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review